4//SEC Filing
Climaco John M 4
Accession 0001683168-23-002830
CIK 0001729427other
Filed
Apr 30, 8:00 PM ET
Accepted
May 1, 6:59 PM ET
Size
7.7 KB
Accession
0001683168-23-002830
Insider Transaction Report
Form 4
Climaco John M
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2023-04-28+1,250→ 46,260 total - Exercise/Conversion
Restricted Stock Units
2023-04-28−1,250→ 60,201 total→ Common Stock (1,250 underlying)
Footnotes (2)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.
Documents
Issuer
CNS Pharmaceuticals, Inc.
CIK 0001729427
Entity typeother
Related Parties
1- filerCIK 0001546797
Filing Metadata
- Form type
- 4
- Filed
- Apr 30, 8:00 PM ET
- Accepted
- May 1, 6:59 PM ET
- Size
- 7.7 KB